The preventive effect of recombinant human hepatocyte growth factor for hepatic steatosis in a rat model of short bowel syndrome
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Mar 2022 · 1 min read
In brief
In brief
Rat model study demonstrates recombinant human hepatocyte growth factor significantly reduces hepatic steatosis and inflammation in short bowel syndrome requiring total parenteral nutrition. Findings suggest HGF may prevent intestinal failure-associated liver disease, a life-threatening TPN complication.
Written by the GCMD Library team from the article.
Purpose
Short bowel syndrome (SBS) patients require total parenteral nutrition (TPN) following massive small bowel resection (SBR), which may cause intestinal failure-associated liver disease (IFALD), a life-threatening complication. Hepatocyte growth factor (HGF) acts as a potent hepatocyte mitogen with anti-inflammatory and antioxidant actions. The present study evaluated the effect of recombinant human HGF (rh-HGF) on SBR and subsequent IFALD using a parentally fed rat model of SBS.
Methods
Rats underwent jugular vein catheterization for continuous TPN and 90% SBR. They were divided into 2 groups: TPN alone (SBS/TPN group: n=7) or TPN plus the intravenous administration of rh-HGF (0.3 mg/kg/day) (SBS/TPN+HGF group: n=7). On day 7, their tissues and stool were harvested to evaluate the effects of HGF.
Results
Regarding the histological findings, based on the nonalcoholic fatty liver disease (NAFLD) activity score, the SBS/TPN+HGF group showed significantly less hepatic steatosis and inflammatory cell infiltration than the SBS/TPN group (NAFLD activity score, 4.00 ± 1.83 vs. 1.00 ± 0.82; p